Patent classifications
C12N2310/52
Hyperbranched polymers and polyplexes and DNA or RNA delivery systems including the same
A hyperbranched polymer includes a hyperbranched, hydrophobic molecular core, respective low molecular weight polyethyleneimine chains attached to at least three branches of the hyperbranched, hydrophobic molecular core, and respective polyethylene glycol chains attached to at least two other branches of the hyperbranched, hydrophobic molecular core. Examples of the hyperbranched polymer may be used to form hyperbranched polyplexes, and may be included in DNA or RNA delivery systems.
OLIGONUCLEOTIDES FOR SARS-CoV-2 MODULATION
- Anastasia Khvorova ,
- Jonathan Watts ,
- Zachary Kennedy ,
- Annabelle Biscans ,
- Bruno Miguel da Cruz Godinho ,
- Chantal Ferguson ,
- Dimas Echeverria Moreno ,
- Ken Yamada ,
- Daniel O'Reilly ,
- Kathryn Monopoli ,
- Vignesh Narayan Hariharan ,
- Qi Tang ,
- Sarah Davis ,
- Samuel Hildebrand ,
- Socheata Ly ,
- Minwook Shin ,
- Pranathi Meda Krishnamurthy ,
- Nicholas McHugh ,
- Jacquelyn Sousa ,
- Jillian Caiazzi ,
- Yann Thillier ,
- Gitali Devi
This disclosure relates to novel SARS-CoV-2 targeting sequences. Novel SARS-CoV-2 targeting oligonucleotides for the treatment of SARS-CoV-2 infection are also provided.
METHODS AND COMPOSITIONS OF RNA NANOSTRUCTURES FOR REPLICATION AND SUB-GENOMIC EXPRESSION BY RNA-DIRECTED RNA POLYMERASE
The present invention is directed to methods and compositions of RNA nanostructures for replication and/or subgenomic expression of gene modulating single-stranded RNA by RNA-directed RNA polymerase-like proteins and the use of such nanostructures for use in a variety of organisms.
Modulation of transthyretin expression
Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.
Engineered nucleic acid-targeting nucleic acids
The present disclosure provides engineered polynucleotide sequences that form scaffolds and nucleoprotein complexes comprising such engineered polynucleotide sequences that form scaffolds and nucleic acid binding proteins. Nucleic acid sequences encoding the engineered polynucleotide sequences that form scaffolds, as well as expression cassettes, vectors and cells comprising such polynucleotide sequences, are described. A variety of methods for making and using the engineered polynucleotide sequences that form scaffolds are also disclosed.
SYNTHETIC AGONISTS OF DNA-PK AND THEIR USE
Polynucleotide constructs are disclosed, that are potent activators of a STING-independent DNA sensing pathway (SIDSP), in which the DNA damage response protein DNA-PK is the sensor of the SIDSP, along with tire heat shock protein HSPA8 as a unique SIDSP target. The polynucleotide constructs of the disclosure are also potent activators of the cGAS-STING DNA sensing pathway. These pathways arm key components of the innate immune response that is important for antiviral immunity, contributes to specific autoimmune diseases, and mediate important aspects of antitumor immunity.
Peptide nucleic acid conjugates
The disclosure is directed to conjugates, e.g. PNA conjugates, as well as methods of employing the conjugates for detecting one or more targets in a biological sample, e.g. a tissue sample.
HYPERBRANCHED POLYMERS AND POLYPLEXES AND DNA OR RNA DELIVERY SYSTEMS INCLUDING THE SAME
A hyperbranched polymer includes a hyperbranched, hydrophobic molecular core, respective low molecular weight polyethyleneimine chains attached to at least three branches of the hyperbranched, hydrophobic molecular core, and respective polyethylene glycol chains attached to at least two other branches of the hyperbranched, hydrophobic molecular core. Examples of the hyperbranched polymer may be used to form hyperbranched polyplexes, and may be included in DNA or RNA delivery systems.
UNIVERSAL DYNAMIC PHARMACOKINETIC-MODIFYING ANCHORS
Therapeutic oligonucleotides comprising universal pharmacokinetic (PK)-modifying anchors are provided. Methods for treating diseases or disorders comprising administering to a subject a therapeutic oligonucleotide comprising one or more universal PK-modifying anchors are provided.
OLIGONUCLEOTIDES AND METHODS FOR PREPARING
Oligonucleotide constructs are described, each comprising a functional element and a coding element, wherein the functional element comprises a functional sequence, the functional sequence comprising a sequence of nucleotides in which one or more, or each, nucleotide is modified and the coding element comprises a coding sequence, the coding sequence comprising a sequence of nucleotides which do not contain the modifications of the functional sequence, wherein the coding sequence encodes the sequence structure of the functional sequence.